This study is exploring a treatment called autologous stem cell transplant (ASCT) for children and young adults (ages 8-25) with severe systemic sclerosis (SSc) or systemic lupus erythematosus (SLE). These are autoimmune diseases where the body's immune system mistakenly attacks its own tissues. ASCT involves using your own stem cells after a special process called CD3/CD19 depletion, which aims to remove harmful immune cells. The main goal is to see if this treatment is safe and works well, specifically looking at how many participants are free from disease progression after two years. This study is for those whose conditions haven't responded to standard treatments.

Study design

This is an interventional study planning to enroll 20 participants. It is a pilot study to evaluate a therapeutic strategy.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for two years to measure progression-free survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.